Shots:
- Teva has entered into a definitive agreement to acquire Emalex Biosciences, incl. its lead asset, ecopipam, expanding its neuroscience pipeline & accelerating Teva’s pivot to growth strategy
- As per the deal, Teva will acquire Emalex for $700M upfront, & ~$200M in commercial milestones, plus royalties on global net sales of ecopipam, subject to regulatory approval; closing is expected in Q3’26
- Ecopipam, a selective dopamine D1 receptor antagonist, is being assessed in the P-III trial for the treatment of children with Tourette syndrome, which showed significant benefit in study’s 1EP, with NDA submission anticipated in H2’26
Ref: Globenewswire | Image: Emalex | Press Release
Related News: Teva Advances Biosimilars Portfolio with Ponlimsi (Denosumab) FDA Approval and Dual Omalizumab Filing Acceptance
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
